Founded in 2018, Kousai has R&D centers in the cities of both Shanghai and Zhongshan. It is a high-tech entitled enterprise focusing on the field of tumor immunotherapy, and is committed to the research, development and industrialization of personalized Dendritic Cells (DC) tumor therapy vaccine (DC vaccine).

Together with the Cancer Hospital affiliated to Tokyo Medical and Dental University, Wuhan University and Fudan University, Kousai has built a high-quality DC technology platform named Eco-DCVax, aiming to develop internationally leading, domestically initiated, inclusive, safe and convenient DC vaccine products with independent intellectual property rights, and thus become a leading and world-class DC vaccine company in China.

Kousai was jointly founded and led by senior industry experts and industrialization team, integrating production, learning and research. The founder and CEO, Dr. Liu Huining, is a doctor of immunology from Tokyo Medical and Dental University in Japan, an MBA from Tulane University in the United States, and a post-doctoral from Harvard Medical School in the United States.

She has rich experience in scientific research and drug development and once worked in BMS, IQVIA and other well-known enterprises, led and participated in more than 50 clinical trials and more than 10 new drug applications, and led several drugs to be listed in many countries around the world.

The DC vaccine developed by Kousai focuses on the disease field where there is no effective treatment method at the moment. It has laid out the related diseases caused by EBV, including lymphoma, post transplant lymphoproliferative disease (PTLD), chronic active EBV infection, nasopharyngeal carcinoma (NPC), gastric cancer, multiple sclerosis and other indications. At the same time, it actively carries out the expansion of multiple disease fields, such as cervical carcinoma, hepatitis, glioma, breast cancer, renal carcinoma, leukemia, AIDS, pancreatic cancer, and so on.

At present, the company has reached cooperation intention with many research institutions to comprehensively promote the application of clinical trials, including exploratory clinical research (IIT) of individualized DC vaccine for various types of tumors, and evaluate the clinical effect of DC vaccine.

In the first half of 2022, Kousai announced a round of Pre-A financing of tens of millions of yuan.